

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 4 JUNE 2026 AND RETIREMENT OF AUDITOR

References are made to the circular (the “**Circular**”) and the notice of annual general meeting of China NT Pharma Group Limited (the “**Company**”) both dated 30 April 2026. Unless otherwise specified, capitalised terms used herein shall have the same meaning as those defined in the Circular.

POLL RESULTS OF THE AGM

The Board announces that save for resolution numbered 3, all the proposed resolutions as set out in the notice of the AGM (the “**Resolutions**”) were duly passed by the Shareholders by way of poll at the AGM.

The poll results of the Resolutions proposed at the AGM were as follows:

Ordinary Resolutions ^(Note 1)		Number of Votes (Approximate %) ^(Note 2)	
		For	Against
1.	To receive and adopt the audited consolidated financial statements of the Company and the reports of the directors and auditors for the year ended 31 December 2025.	214,308,089 (100.00%)	0 (0.00%)
2(a)(i).	To re-elect Ms. Chin Yu as a non-executive director.	214,308,089 (100.00%)	0 (0.00%)
2(a)(ii).	To re-elect Dr. Zhao Yubiao as an independent non-executive director.	214,308,089 (100.00%)	0 (0.00%)
2(a)(iii).	To re-elect Mr. Lou Yongbin as a non-executive director.	214,308,089 (100.00%)	0 (0.00%)
2(b).	To authorise the board of directors to fix the remuneration of the directors of the Company.	214,308,089 (100.00%)	0 (0.00%)

Ordinary Resolutions ^(Note 1)		Number of Votes (Approximate %) ^(Note 2)	
		For	Against
3.	To re-appoint Moore CPA Limited as the auditors of the Company and to authorise the board of directors of the Company to fix their remuneration.	7,253,850 (3.38%)	207,054,239 (96.62%)
4(A).	To grant a general mandate to the directors of the Company to allot, issue and deal with additional shares not exceeding 20% of the issued shares of the Company.	214,308,089 (100.00%)	0 (0.00%)
4(B).	To grant a general mandate to the directors of the Company to repurchase shares not exceeding 10% of the issued shares of the Company.	214,308,089 (100.00%)	0 (0.00%)
4(C).	Conditional upon the passing of ordinary resolutions No. 4(A) and No. 4(B), to extend the authority given to the directors of the Company pursuant to ordinary resolution No. 4(A) to issue shares by adding to the number of shares of the Company which may be allotted by the directors of the Company pursuant to such general mandate of an amount representing the number of shares repurchased under ordinary resolution No. 4(B).	214,308,089 (100.00%)	0 (0.00%)

Notes:

1. The full text of the Resolutions was set out in the notice of the AGM dated 30 April 2026.
2. The number of votes and percentage of voting Shares are based on the total number of the issued Shares held by the Shareholders who cast votes at the AGM in person or by proxy.

The AGM was presided over by Ms. Chin Yu, a non-executive Director. All Directors attended the AGM either in person or by electronic means.

As at the date of the AGM, the number of issued Shares was 948,997,694 Shares, which was the total number of Shares entitling the Shareholders to attend and vote for or against the Resolutions at the AGM.

There were no Shares which entitled the Shareholders thereof to attend but abstain from voting in favour of the Resolutions at the AGM as set out in Rule 13.40 of the Listing Rules, and no Shareholders were required to abstain from voting at the AGM under the Listing Rules. There were no parties who had stated their intention in the Circular to vote against or to abstain from voting on any of the Resolutions at the AGM.

There were (i) no treasury shares held by the Company (including any treasury shares held or deposited with Central Clearing and Settlement System) as at the date of the AGM and as such no voting rights of treasury shares have been exercised at the AGM; and (ii) no repurchased Shares which are pending cancellation and should be excluded from the total number of Shares in issue for the purpose of the Resolutions.

Tricor Investor Services Limited, the branch share registrar and transfer office of the Company in Hong Kong, was appointed as the scrutineer for the vote-taking at the AGM.

As more than 50% of the votes were cast in favour of resolutions nos. 1, 2(a)(i), 2(a)(ii), 2(a)(iii), 2(b), 4(A), 4(B) and 4(C), at the AGM, such resolutions were duly passed as ordinary resolutions of the Company. As more than 50% of the votes were cast against resolution no. 3, resolution no. 3 was not passed as an ordinary resolution at the AGM.

RETIREMENT OF AUDITOR

As resolution no. 3 regarding the re-appointment of Moore CPA Limited as the Company's auditor was not passed at the AGM, Moore CPA Limited retired as the Company's auditor with effect from the conclusion of the AGM.

The Company is liaising with Moore CPA Limited to obtain its confirmation as to whether there are any matters that need to be brought to the attention of the Shareholders in relation to the retirement, and has not yet received such confirmation as at the date of this announcement. A further announcement will be made upon receipt of such confirmation in accordance with Rule 13.51(4) of the Listing Rules.

The Company is in the process of identifying a suitable replacement to fill the vacancy resulted from the retirement of Moore CPA Limited. The Board will convene an extraordinary general meeting as soon as practicable to propose the appointment of a new auditor. Further announcement(s) will be made by the Company in accordance with the Listing Rules.

By order of the Board
China NT Pharma Group Company Limited
Chairman
NG Tit

Hong Kong, 4 June 2026

As at the date of this announcement, the executive directors are Mr. Ng Tit and Ms. Ng, Anna Ching Mei; the non-executive directors are Dr. Qian Wei, Ms. Chin Yu and Mr. Lou Yongbin; and the independent non-executive directors are Mr. Yu Tze Shan Hailson, Mr. Kwok Che Chung and Dr. Zhao Yubiao.